Silencing endothelin-3 expression attenuates the malignant behaviors of human melanoma cells by regulating SPARC levels

Abstract

Endothelin-3 (ET-3) is aberrantly expressed in both metastatic melanoma tissues and cultured melanoma cells. Our previous work showed that ET-3 could promote survival of metastatic melanoma cells via its altered expression. In this study, we investigated the mechanisms responsible for these gene-induced phenotypes in melanoma cells. An ET-3 gene sequence-specific shRNA vector pLVTHM-ET3-RNAi was constructed and transfected into human malignant melanoma cells A375 and MMRU, and the resultant molecular events and cellular changes were examined. As compared with the empty-vector group, cell proliferation was slowed down, and the growth inhibition rates were 38.9% in A375 cells and 38.4% in MMRU cells after transfection. In addition, cell invasion capability was also inhibited, with a reduction of 62.2% in A375 cells and 54.3% in MMRU cells. The percentage of apoptotic cells was found to increase. Meanwhile, in both cell lines, secreted protein acidic and rich in cysteine (SPARC) levels were down-regulated together with inhibition of its upstream signaling molecule, NF-κB. Thus, the current results suggested that down-regulated expression of ET3 attenuates the malignant behaviors of human melanoma cells partially by decreasing the expression of SPARC and NF-κB.

Keywords

melanoma / short hairpin RNA / endothelin-3 / nuclear factor-kappa B / secreted protein acidic and rich in cysteine

References

[1] GodarDE. Worldwide increasing incidences of cutaneous malignant melanoma. J Skin Cancer, 2011, 2011: 858425

[2] TsaoH, AtkinsMB, SoberAJ. Management of cutaneous melanoma. N Engl J Med, 2004, 351(10): 998-1012

[3] CaiH, NiA, LiW, et al.. Inhibition of melanoma cell proliferation by targeting Wnt/beta-catenin pathway through Sox4 RNA interference. J Huazhong Univ Sci Technol [Med Sci], 2011, 31(4): 565-569

[4] Saldana-CaboverdeA, KosL. Roles of endothelin signaling in melanocyte development and melanoma. Pigment Cell Melanoma Res, 2010, 23(2): 160-170

[5] KuriharaH, KuriharaY, NagaiR, et al.. Endothelin and neural crest development. Cell Mol Biol (Noisy-le-grand), 1999, 45(5): 639-651

[6] McCallionAS, ChakravartiA. EDNRB/EDN3 and Hirschsprung disease type II. Pigment Cell Res, 2001, 14(3): 161-169

[7] LahavR, DupinE, LecoinL, et al.. Endothelin 3 selectively promotes survival and proliferation of neural crest-derived glial and melanocytic precursors in vitro. Proc Natl Acad Sci USA, 1998, 95(24): 14 214-14 219

[8] DemunterA, De Wolf-PeetersC, DegreefH, et al.. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch, 2001, 438(5): 485-491

[9] LahavR, SuvaML, RimoldiD, et al.. Endothelin receptor B inhibition triggers apoptosis and enhances angiogenesis in melanomas. Cancer Res, 2004, 64: 8945-8953

[10] LinN, HuangC, TianJ, et al.. The expression of endothelin receptor B in melanoma cells A375 and Sk-mel-1 and the proliferative effects of endothelin 3 on A375 cells. J Huazhong Univ Sci Technol [Med Sci], 2007, 27(5): 611-613

[11] BittnerM, MeltzerP, ChenY, et al.. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature, 2000, 406(6795): 536-540

[12] TangL, SuM, ZhangY, et al.. Endothelin-3 is produced by metastatic melanoma cells and promotes melanoma cell survival. J Cutan Med Surg, 2008, 12(2): 64-70

[13] BrandM, Le MoullecJM, CorvolP, et al.. Ontogeny of endothelins-1 and -3, their receptors, and endothelin converting enzyme-1 in the early human embryo. J Clin Invest, 1998, 101(3): 549-559

[14] LahavR, ZillerC, DupinE, et al.. Endothelin 3 promotes neural crest cell proliferation and mediates a vast increase in melanocyte number in culture. Proc Natl Acad Sci USA, 1996, 93(9): 3892-3897

[15] DupinE, GlavieuxC, VaigotP, et al.. Endothelin 3 induces the reversion of melanocytes to glia through a neural crest-derived glial-melanocytic progenitor. Proc Natl Acad Sci USA, 2000, 97(14): 7882-7887

[16] NagarajuGP, SharmaD. Anti-cancer role of SPARC, an inhibitor of adipogenesis. Cancer Treat Rev, 2011, 37(7): 559-566

[17] MassiD, FranchiA, BorgognoniL, et al.. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol, 1999, 30(3): 339-344

[18] ShiQ, BaoS, SongL, et al.. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases. Oncogene, 2007, 26(28): 4084-4094

[19] ShiQ, BaoS, MaxwellJA, et al.. Secreted protein acidic, rich in cysteine (SPARC), mediates cellular survival of gliomas through AKT activation. J Biol Chem, 2004, 279(50): 52 200-52 209

[20] PradaF, BenedettiLG, BravoAI, et al.. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. J Invest Dermatol, 2007, 127(11): 2618-2628

[21] HuangCZ, JinT, JuanT, et al.. Endothelin signaling axis activates osteopontin expression through PI3 kinase pathway in A375 melanoma cells. J Dermatol Sci, 2008, 52(2): 130-132

[22] DhawanP, SinghAB, EllisDL, et al.. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res, 2002, 62(24): 7335-7342

[23] FenouilleN, PuissantA, TichetM, et al.. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene, 2011, 30(49): 4887-4900

[24] FenouilleN, TichetM, DufiesM, et al.. The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion. PloS One, 2012, 7(7): e40378